Compare · NVO vs RADX
NVO vs RADX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Radiopharm Theranostics Limited (RADX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RADX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 11121.5x RADX ($15.6M).
- Over the past year, NVO is down 28.6% and RADX is down 85.4% - NVO leads by 56.8 points.
- RADX has been more active in the news (8 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 2 for RADX).
- Company
- Novo Nordisk A/S
- Radiopharm Theranostics Limited
- Price
- $38.82-1.05%
- $1.05-8.70%
- Market cap
- $173.66B
- $15.6M
- 1M return
- -10.14%
- -40.68%
- 1Y return
- -28.57%
- -85.42%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 8
- Recent ratings
- 25
- 2
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest RADX
- SEC Form 6-K filed by Radiopharm Theranostics Limited
- Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
- SEC Form 6-K filed by Radiopharm Theranostics Limited
- SEC Form 20-F filed by Radiopharm Theranostics Limited
- SEC Form 6-K filed by Radiopharm Theranostics Limited
- SEC Form EFFECT filed by Radiopharm Theranostics Limited
- SEC Form 424B3 filed by Radiopharm Theranostics Limited
- SEC Form 6-K filed by Radiopharm Theranostics Limited
- Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting
- SEC Form 6-K filed by Radiopharm Theranostics Limited